Overview
Extendicare Q3 revenue beats analyst expectations
Adjusted EBITDA increased driven by home health care growth
Company completed acquisition of Closing the Gap for C$75.1 mln in cash
Outlook
Company anticipates C$1.1 mln in annualized cost synergies from Closing the Gap acquisition
Company sees opportunity for further acquisitions in fragmented seniors care market
Result Drivers
HOME HEALTH CARE GROWTH - Co attributes Q3 revenue increase to 24.6% growth in home health care ADV, including contributions from Closing the Gap
ACQUISITIONS BOOST - Revenue growth driven by acquisition of Closing the Gap and nine Class C LTC homes
LONG-TERM CARE IMPROVEMENTS - Co cites improved LTC funding and occupancy rates as contributors to revenue growth
Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Revenue
Beat
C$440.28 mln
C$415.40 mln (2 Analysts)
Q3 Net Income
C$24.12 mln
Q3 Adjusted EBITDA
C$50.77 mln
Q3 Adjusted FFO
C$29.54 mln
Q3 Adjusted EBITDA Margin
11.50%
Q3 Operating Expenses
C$374.37 mln
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the healthcare facilities & services peer group is "buy"
Wall Street's median 12-month price target for Extendicare Inc is C$16.50, about 2.2% above its November 10 closing price of C$16.14
The stock recently traded at 17 times the next 12-month earnings vs. a P/E of 14 three months ago
Press Release: ID:nGNX1Xw2rM
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)